Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST ® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results